Nicolas Coquelle

Nicolas Coquelle

Auto-generated profile, based on publicly available information

Nicolas Coquelle

Univ. Grenoble Alpes, CEA, CNRS, Institut de Biologie Structurale

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2017 in Science
Verified
Journal Article
Closed access
PDF file
ETEinav Tayeb-Fligelman
Einav Tayeb-Fligelman
OTOrly Tabachnikov
Orly Tabachnikov
AMAsher Moshe
Asher Moshe
OGOrit Goldshmidt-Tran
Orit Goldshmidt-Tran
MSMichael R. Sawaya
Michael R. Sawaya
MLMeytal Landau
Meytal Landau
What's in a fold?: Bacterially secreted peptides known as PSMs (phenol-soluble modulins) stimulate inflammatory responses, lyse human cells, and contribute to biofilm structuring. PSMα3 is a virulent 22-residue amyloid peptide secreted by Staphylococcus aureus. Tayeb-Fligelman et al. present a high-resolution structure encompassing the full length of the amyloid's sequence. This structure reveals an unexpected departure from the common amyloid cross-β folded architecture. Instead, PSMα3 forms amphipathic α-helices that are folded to stack perpendicular to the fibril axis into sheets. This unusual cross-α structure was important for fibril toxicity. Science , this issue p. 831

29 September 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BBBoris Brus
Boris Brus
UKUrban Košak
Urban Košak
STSamo Turk
Samo Turk
APAnja Pišlar
Anja Pišlar
NCNicolas Coquelle
Nicolas Coquelle
SGStanislav Gobec
Stanislav Gobec

11 September 2017 in Nature Chemistry
Verified
Journal Article
Closed access
PDF file
NCNicolas Coquelle
Nicolas Coquelle
MSMichel Sliwa
Michel Sliwa
JWJoyce Woodhouse
Joyce Woodhouse
GSGiorgio Schirò
Giorgio Schirò
VAVirgile Adam
Virgile Adam
MWMartin Weik
Martin Weik

21 December 2016 in Scientific Reports
Verified
Journal Article
Open access
UKUrban Košak
Urban Košak
BBBoris Brus
Boris Brus
Damijan KnezDamijan Knez
Damijan Knez
RŠRoman Šink
Roman Šink
SŽSimon Žakelj
Simon Žakelj
SGStanislav Gobec
Stanislav Gobec
Alzheimer’s disease (AD) is characterized by severe basal forebrain cholinergic deficit, which results in progressive and chronic deterioration of memory and cognitive functions. Similar to acetylcholinesterase, butyrylcholinesterase (BChE) contributes to the termination of cholinergic neurotransmission. Its enzymatic activity increases with the disease progression, thus classifying BChE as a viable therapeutic target in advanced AD. Potent, selective and reversible human BChE inhibitors were developed. The solved crystal structure of human BChE in complex with the most potent inhibitor reveals its binding mode and provides the molecular basis of its low nanomolar potency. Additionally, this compound is noncytotoxic and has neuroprotective properties. Furthermore, this inhibitor moderately crosses the blood-brain barrier and improves memory, cognitive functions and learning abilities of mice in a model of the cholinergic deficit that characterizes AD, without producing acute cholinergic adverse effects. Our study provides an advanced lead compound for developing drugs for alleviating symptoms caused by cholinergic hypofunction in advanced AD.

14 June 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
MLMegan S. Lee
Megan S. Lee
RGRuth Green
Ruth Green
SMSylvia M. Marsillac
Sylvia M. Marsillac
NCNicolas Coquelle
Nicolas Coquelle
RWR. Scott Williams
R. Scott Williams
MGMark Glover
Mark Glover
Genetic screening of the breast and ovarian cancer susceptibility gene BRCA1 has uncovered a large number of variants of uncertain clinical significance. Here, we use biochemical and cell-based transcriptional assays to assess the structural and functional defects associated with a large set of 117 distinct BRCA1 missense variants within the essential BRCT domain of the BRCA1 protein that have been documented in individuals with a family history of breast or ovarian cancer. In the first method, we used limited proteolysis to assess the protein folding stability of each of the mutants compared with the wild-type. In the second method, we used a phosphopeptide pull-down assay to assess the ability of each of the variants to specifically interact with a peptide containing a pSer-X-X-Phe motif, a known functional target of the BRCA1 BRCT domain. Finally, we used transcriptional assays to assess the ability of each BRCT variant to act as a transcriptional activation domain in human cells. Through a correlation of the assay results with available family history and clinical data, we define limits to predict the disease risk associated with each variant. Forty-two of the variants show little effect on function and are likely to represent variants with little or no clinical significance; 50 display a clear functional effect and are likely to represent pathogenic variants; and the remaining 25 variants display intermediate activities. The excellent agreement between the structure/function effects of these mutations and available clinical data supports the notion that functional and structure information can be useful in the development of models to assess cancer risk. Cancer Res; 70(12); 4880–90. ©2010 AACR.

22 December 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
UKUrban Košak
Urban Košak
BBBoris Brus
Boris Brus
Damijan KnezDamijan Knez
Damijan Knez
SŽSimon Žakelj
Simon Žakelj
JTJurij Trontelj
Jurij Trontelj
SGStanislav Gobec
Stanislav Gobec